- Home
- REGN vs DDOG Comparison
REGN vs DDOG Comparison
Compare REGN & DDOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- DDOG
- Stock Information
- Founded
- REGN 1988
- DDOG 2010
- Country
- REGN United States
- DDOG United States
- Employees
- REGN N/A
- DDOG N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- DDOG Computer Software: Prepackaged Software
- Sector
- REGN Health Care
- DDOG Technology
- Exchange
- REGN Nasdaq
- DDOG Nasdaq
- Market Cap
- REGN 59.9B
- DDOG 51.4B
- IPO Year
- REGN 1991
- DDOG 2019
- Fundamental
- Price
- REGN $558.87
- DDOG $135.60
- Analyst Decision
- REGN Buy
- DDOG Buy
- Analyst Count
- REGN 21
- DDOG 31
- Target Price
- REGN $823.86
- DDOG $146.69
- AVG Volume (30 Days)
- REGN 940.4K
- DDOG 9.9M
- Earning Date
- REGN 08-01-2025
- DDOG 08-07-2025
- Dividend Yield
- REGN 0.63%
- DDOG N/A
- EPS Growth
- REGN 5.03
- DDOG 45.28
- EPS
- REGN 39.67
- DDOG 0.47
- Revenue
- REGN $14,214,200,000.00
- DDOG $2,834,575,000.00
- Revenue This Year
- REGN N/A
- DDOG $23.05
- Revenue Next Year
- REGN $6.65
- DDOG $19.10
- P/E Ratio
- REGN $14.09
- DDOG $286.02
- Revenue Growth
- REGN 5.38
- DDOG 25.54
- 52 Week Low
- REGN $476.49
- DDOG $81.63
- 52 Week High
- REGN $1,211.20
- DDOG $170.08
- Technical
- Relative Strength Index (RSI)
- REGN 54.16
- DDOG 43.55
- Support Level
- REGN $541.61
- DDOG $141.75
- Resistance Level
- REGN $563.59
- DDOG $152.24
- Average True Range (ATR)
- REGN 15.37
- DDOG 3.39
- MACD
- REGN -0.75
- DDOG -1.48
- Stochastic Oscillator
- REGN 41.57
- DDOG 8.12
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About DDOG Datadog Inc.
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered via software as a service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of applications throughout their businesses.